Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Nosocomial Infection Rates Fall in Single-Patient Rooms

By HospiMedica International staff writers
Posted on 11 Sep 2019
A new study suggests that single-patient rooms help prevent drug-resistant organism colonization, resulting in significantly reduced rates of hospital-acquired infection (HAI).

Researchers at McGill University (Montreal, Canada) conducted a time-series analysis study that looked at changes in the rates of several infections over a period spanning 65 months, before and after evacuation of the old 417-bed Royal Victoria Hospital, which contained many 3-4 person ward-type rooms, to the new 350-bed Glen site facility, which exclusively features private rooms, most of which are equipped with individual toilets and showers and easy access to sinks for hand-washing. More...
The synchronized move of all patients occurred on April 26, 2015.

The researchers then compared rates of vancomycin-resistant Enterococcus (VRE) and methicillin-resistant Staphylococcus aureus (MRSA) colonization, VRE and MRSA infection, and Clostridium difficile infection (CDI) per 10,000 patient-days. The results revealed an immediate and sustained reduction in nosocomial VRE and MRSA colonization rates, as well as VRE infection, following the move to the Glen site facility. Rates of CDI and MRSA infection, however, did not decrease. The study was published on August 19, 2019, in JAMA: Internal Medicine.

“The single-patient room experience at the Glen site has many benefits - privacy, confidentiality, comfort, reduced noise, and improved quality of sleep. Importantly, this study also found that private rooms might help reduce life-threatening infections,” said lead author Emily Gibson McDonald, MD. “We suspect that much like VRE, the spread of resistant gram-negative bacteria, particularly those which are emerging in Canada and concentrated in hospitals, could be more easily contained in an exclusively single-patient facility, when combined with continued infection control and hand hygiene measures, and a better use of antibiotics.”

“While we cannot prove causation in a study like this, the changes were so immediate and so striking that we are fairly convinced they were mostly a result of the move,” said senior author infectious diseases specialist Todd Campbell Lee, MD, of the McGill University Health Centre (MUHC). “However, the ongoing effort by the MUHC staff to keep the facilities rigorously clean, encourage excellent staff hand hygiene, and intervene more aggressively when outbreaks are discovered has helped maintain our rates fairly low.”

Four main pathogens are involved in HAIs, which are Clostridium difficile, MRSA, VRE, and Acinetobacter baumannii, which may persist on environmental surfaces for days or weeks. Clostridium difficile spores can persist on environmental surfaces for up to five months. Studies have shown that only 50% of environmental surfaces in a typical patient room may be effectively disinfected.

Related Links:
McGill University


Gold Member
Real-Time Diagnostics Onscreen Viewer
GEMweb Live
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Floor‑Mounted Digital X‑Ray System
MasteRad MX30+
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: The collaboration will integrate Masimo’s innovations into Philips’ multi-parameter monitoring platforms (Photo courtesy of Royal Philips)

Philips and Masimo Partner to Advance Patient Monitoring Measurement Technologies

Royal Philips (Amsterdam, Netherlands) and Masimo (Irvine, California, USA) have renewed their multi-year strategic collaboration, combining Philips’ expertise in patient monitoring with Masimo’s noninvasive... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.